Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

My name is Raph Hamers, I’m a senior clinical scientist at the Eijkman Oxford Clinical Research Unit, I’m based in Jakarta Indonesia and my work is on clinical trials.

The main challenges of doing clinical trials in Indonesia is that clinical trials require a high level of expertise and specific skill sets. I think in Indonesia some institutions have that capacity but in general I would say there’s still a need to invest and develop that capacity. The importance of doing clinical trials is that it can help Indonesians to advance healthcare and advance outcomes for patients.

We’re currently running a phase 3 clinical trial in adult patients with HIV infection that have tuberculosis meningitis. The aim of the trial is to evaluate if the addition of an anti-inflammatory drug, dexamethasone, helps to improve the outcome of patients with tuberculosis meningitis. Tuberculosis meningitis is a complication of tuberculosis and it’s the most severe form; people with that form of meningitis often die and if you survive you usually have severe neurological disabilities.

In Jakarta we recently established a new laboratory, the Universities of Indonesia and Oxford Clinical Research laboratory, denoted IOCRL, and the aim of the new laboratory is to expand the agenda on clinical research. We seek in collaboration with our partners to develop new lines of research in infectious diseases that are important to public health. We train young scientists to develop specific skill sets to do the trials; we will have a laboratory that will serve to do all of the lab testing for clinical trials, and I think that new capacity is important to strengthen clinical research in Indonesia.

The Oxford unit in Jakarta has three themes of research. Historically the focus has been on malaria research; this line of research is led by Professor Kevin Baird and has focused on clinical trials mostly and the treatment and diagnoses of Plasmodium vivax malaria. The second line of research is on geospatial epidemiology led by Dr Iqbal Elyazar; his team are using big data approaches to see how they can map infectious diseases in Indonesia and correlate that to factors that determine the burdens. And the most recent line of research is clinical research under my responsibility. In this line of research we focus on CNS infections (central nervous system); the clinical trial on tuberculosis meningitis is one example, currently our most important project.

I think the strength of our unit is that we work very closely with our local partners: we identify the topics we work on based on their advice and based on our mutual interests; I think that’s a very strong component of our work. There are a lot of good people with great ideas, they are well trained, and they are great professionals to work with. What surprised me is that there seems to be a lack of collaborations. People are working very independently but are not necessarily sharing ideas and sharing efforts of collaborating to the extent they could be. I think there’s a great opportunity there if people can find each other more often, then the projects they do and the ideas they have could have more impact.

Our research is important because of our location, primarily. Indonesia is a very populous country: it’s the 4th most populous country in the world and it has a huge burden of infectious diseases. Every year there are estimates of more than 1 million new TB cases, more than 1 million new malaria cases, HIV epidemic is growing at a fast rate - it was estimated that in 2016 there were 48,000 new infections - and then in addition there are many other infectious diseases that are still very common. There is a lot to do, but nonetheless I think Indonesia is one of those countries that are under-represented in international discussions, the voice of Indonesia is generally not well represented in global health and medical science. I think there’s a great need for investments in research to advance the healthcare situation in the country.

I look at translational medicine as generating scientific data that can be used directly to improve patient care. The model that we use mostly is focused on patient-centred research clinical trials; by generating that kind of information we can dive deeper and use those data to unravel biological mechanisms. By combining that more mechanistic information with clinical data, I think it’s a very powerful model to advance health care; to me that is translational medicine.

Raph Hamers

Dr Raph Hamers manages the recently established Universities of Indonesia and Oxford Clinical Research Laboratory (IOCRL). This administrative, regulatory, and technical hub for clinical trials provides an integrated medium for training, education, public engagement and development of a broader collaborative clinical research agenda.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Juan Carrique-Mas: Antimicrobial resistance in poultry production

Many households in Vietnam raise animals for food production, particularly chickens, using large amounts of antimicrobials with no veterinary support, and those antimicrobials find their way into the food chain. The ViParc project conducts intervention trials similar to human clinical trials, to help farmers reduce the level of antimicrobials used when raising chickens.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.